ClinicalTrials.gg
RecruitingNCT03594422Updated Apr 9, 2026

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

A Phase 1 interventional study of HQP1351 in Gastrointestinal Stromal Tumor (GIST) and Solid Tumor, Adult, sponsored by Ascentage Pharma Group Inc.. Recruiting at 6 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2018; still recruiting 8 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Gastrointestinal Stromal Tumors with a site in China — 24 open to participants now, 28 under way, 4 of them phase 3. Gastrointestinal Stromal Tumors · China.

Planned enrollment
21st of 46
100 · median 100
Started
2018
with 4 others
Phase 1
7 of 69
1 open now
Primary completion
2027-12
later than 20 of 27 live
Registered
20th of 69
by date

Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, this one is the 21st largest by planned enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2018, is one of 7 in phase 1, reaches primary completion later than 20 of the 27 other live ones, and was the 20th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

24 of the 69 studies in Gastrointestinal Stromal Tumors with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Gastrointestinal Stromal Tumors with a site in China, or all of them as a file.
02

Study summary

This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.

Read the detailed description

The primary objective of this phase 1 study is to determine the RP2D of HQP1351 in patients with GIST or other solid tumors. The secondary objective is to assess the safety, tolerability, PK and preliminary anti-tumor activities of HQP1351 in Patients With GIST or Other Solid Tumors.

03

Conditions studied

  • Gastrointestinal Stromal Tumor (GIST)
  • Solid Tumor, Adult
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or not pregnant or lactating women, age≥12years.
  2. Advanced and/or GIST or other solid tumors, confirmed by histology and/or cytology. GIST patients must be primary resistant to imatinib (tumor progresses within 6 months imatinib treatment, or succinate dehydrogenase B (SDHB) deficient confirmed by immunohistochemistry, or NF1 mutation), OR imatinib or imatinib and at least one other TKI treatment failure (after imatinib or other TKI treatment for more than 6 months, tumor progress again after achieving tumor remission or stability).
  3. ≤ 2.
  4. Estimated survival at least 3 months.
  5. Adequate hematologic and bone marrow functions.
  6. Adequate renal and liver function.
  7. Heart function index:

    • Troponin(I/T) ≤ ;
    • >40%;
    • ≤ 450 ms in male or ≤ 470 ms in female.
  8. Negative serum pregnancy test (for women of ) documented within the 24-hour prior to the first dose of product.
  9. Willing to use by a method that is deemed effective by the investigator by Subject and their partners throughout the treatment period and for at least 30 days following the last dose of study drug.
  10. Ability to understand and willingness to sign a written form (the consent form must be signed by the subject prior to any study-specific procedures).
  11. Willing and ability to comply with study procedures and follow-up examination.

Exclusion criteria

Exclusion Criteria:

  1. Received any anti-cancer chemotherapy, biological agent treatment (e.g. Monoclonal antibody), immunotherapy (e.g. IFN) or radiotherapy with 28 days or 5 times half- time before first dose of HQP1351.
  2. Received any TKIs within 14 days before first dose of HQP1351.
  3. Attended any clinical trials on other drugs within 14 days before first dose of HQP1351.
  4. Have not recovered (> Grade 1 by , v. 4.0) from AEs (except alopecia) due to agents previously administered.
  5. Malabsorption syndrome or other diseases that affect the absorption of oral drugs.
  6. Cardiovascular diseases of clinical significance, uncontrollable or active, including but not limited to: history of myocardial infarction; unstable history of angina pectoris; a history of congestive heart failure or lower (LVEF) than normal limit within 6 months; the history of atrial arrhythmias was judged by the researchers to have important clinical significance; history of ventricular arrhythmias, etc.
  7. Hypertension was still poorly controlled after medication treatment (SBP > 140 mmHg and/or DBP > 90 mmHg).
  8. Concurrent use any medication led to prolong .
  9. Pulmonary mean arterial pressure>35 mmHg by ECHO.
  10. Significant severe cardiovascular conditions during previous TKI treatment.
  11. Uncontrollable hypertriglyceridemia.
  12. Performed major surgery (except for intravenous catheterization or bone marrow ) within 14 days of first dose of HQP1351.
  13. Arterial thrombosis or embolism events such as cerebrovascular accident (including , TIA), or venous thrombosis events or pulmonary embolism within 6 months before the first dose of HQP1351 or deep vein thrombosis within 3 months before the first dose of HQP1351.
  14. .
  15. Had other primary malignant tumors in the last three years (exception of the tumors being cured for 5 years or more, or complete removal of non-melanoma skin cancer or successful treatment of carcinoma in situ, or the controlled prostate cancer).
  16. Had active, symptomatic infections (including known infections of , viral hepatitis (A, B, or C)). If there is no history of infection, screening is not required.
  17. Subjects who are known to be allergic to pharmaceutical ingredients or their analogs.
  18. Pregnancy or lactation, or expect to be pregnant during the study period.
  19. According to the judgment of the investigator or sponsor, any symptoms or disease of the subject may jeopardize the safety or safety assessment of the subject.
  20. Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    HQP1351 30mg

    30 mg QOD(Minor subjects will be enrolled based on weight)

    Drug: HQP1351

  • Experimental
    HQP1351 40mg

    40 mg QOD(Minor subjects will be enrolled based on weight)

    Drug: HQP1351

  • Experimental
    HQP1351 50mg

    50 mg QOD

    Drug: HQP1351

  • Experimental
    HQP1351 20mg

    20 mg QOD (Minor subjects will be enrolled based on weight)

    Drug: HQP1351

Interventions

  • HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.

06

What researchers measure

Primary outcomes

  1. Safety and tolerance

    Patients with HQP1351 treatment related adverse events (AE), serious adverse events (SAE) will be assessed according NCI CTCAE Version 4.03.

    Time frame: 30 days after the last dose of HQP1351

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of HQP1351 on Day 1 and Day 27 post HQP1351 treatment on cycle 1.

    Pharmacokinetic evaluation

    Time frame: 28 days

  2. Area under the plasma concentration versus time curve (AUC) of HQP1351 on Day 1 and Day 27 post HQP1351 treatment on cycle 1.

    Pharmacokinetic evaluation

    Time frame: 28 days

  3. Anti-tumor activities of HQP1351

    Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1

    Time frame: 3-60 months

07

Study locations

6 of 6 sites recruiting
  • Sun-Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Ruihua Xu, Professor · Contactruihxu@163.com · +86-20-87343468
    • Zhiwei Zhou, Professor · Contact
    • Ruihua Xu, Professor · Principal investigator
    • Zhiwei Zhou, Professor · Principal investigator
  • Guangdong general hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Yong Li, Professor · Contact
    • Yong Li, Professor · Principal investigator
  • Henan cancer hospital
    Zhengzhou, Henan, China
    Recruiting
    • Xiangbin Wan, Professor · Contact
    • Xiangbin Wan, Professor · Principal investigator
    • Ning Li, Professor · Principal investigator
  • Union Hospital Tongji Medical College of Huazhong University of Science ang Technology
    Wuhan, Hubei 215316, China
    Recruiting
    • Kaixiong Tao, Ph.D · Contact
    • Kaixiong Tao, Ph.D · Principal investigator
  • Chinese PLA general hospital, Beijing, China
    Beijing, China
    Recruiting
    • Xin Wu, Professor · Contact
    • Xin Wu, Professor · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, China
    Recruiting
    • Ye Zhou, Professor · Contact
    • Ye Zhou, Professor · Principal investigator
08

References and documents

Publications

  • Qiu HB, Liang Z, Yang J, Zhou Y, Zhou ZW, Wan XB, Li N, Tao KX, Li Y, Wu X, Yang C, Chen Z, Wang H, Men L, Xiong Y, Liu L, Yang D, Zhai Y, Xu RH. Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research. Signal Transduct Target Ther. 2025 Nov 4;10(1):361. doi: 10.1038/s41392-025-02456-9. PubMed 41184234 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Dec 2027, 113 months after the start.

Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's planned 113 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2018
First posted
Jul 20, 2018
StartActual
Jul 11, 2018
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03594422
Collaborators
HealthQuest Pharma Inc.
Responsible party
Sponsor
First posted
Jul 20, 2018
Start date
Jul 11, 2018
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 9, 2026

Study contacts

Yifan Zhai, M.D., Ph.D.
Contact
yzhai@ascentagepharma.com
+86-20-28069260
Ruihua Xu, Professor
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olverembatinib

Start the discussion